Table 2.
Epitope mapping and characterization of mAbs.
| MAb (K7-) | Total number | S1 (D614G) | eRBD | eRBD (N501Y) | eRBD (E484K) | S B.1.1.529 | S BA.5 |
Epitope |
|---|---|---|---|---|---|---|---|---|
| 84, 90, 101, 108, 119, 148, 183, 184, 185 | 9 | + | + | + | + | + | + | R12 |
| 212, 216 | 2 | + | + | + | + | - | - | R12 |
| 62, 82 | 2 | - | + | + | + | - | - | R12 |
| 159 | 1 | + | + | - | - | + | + | R6 |
| 149 | 1 | + | + | - | - | + | + | R16 |
| 150 | 1 | + | + | - | - | - | - | R16 |
| 64, 65, 67, 80, 83, 85, 87, 103, 105, 106, 112, 125, 129, 132, 138, 140, 141, 144, 154, 155, 156, 168, 174, 186, 198, 200, 201, 202, 209, 210, 215 | 31 | + | + | - | - | + | + | un |
| 166 | 1 | + | + | - | - | + | - | un |
| 187 | 1 | + | + | - | - | - | - | un |
| 63, 68, 69, 72, 73, 74, 76, 78, 86, 88, 89, 91, 94, 97,99, 102, 104, 107, 109, 113, 115, 121, 124, 126, 127, 130, 131, 134, 135, 136, 145, 146, 151, 161, 164, 165, 167, 171, 176, 178, 179, 180, 188, 190, 191, 192, 195, 196, 197, 205, 206, 208, 211 | 53 | + | - | - | - | + | - | un |
| 61, 66, 70, 77, 79, 92, 93, 98, 100, 111, 114, 116, 117, 133, 137, 139, 142, 143, 147, 153, 157, 181, 182, 189, 199, 204, 213 | 27 | + | - | - | - | + | + | un |
| 81, 118, 152, 158, 160, 162, 169, 172, 193, 194, 217 | 11 | + | - | - | - | - | - | un |
| 123, 214 | 2 | - | + | - | - | - | - | un |
| 71, 75, 120, 122, 170, 173, 175, 177, 207 | 9 | - | - | - | - | - | - | un |
S1(D614G), mutant SARS-CoV-2 S1(D614G); eRBD, eukaryotic SARS-CoV-2 RBD; eRBD(N501Y), mutant eukaryotic SARS-CoV-2 RBD(N501Y); eRBD(E484K), mutant eukaryotic SARS-CoV-2 RBD(E484K); +, detectable reaction; -, undetectable reaction; R6, 391CFTNVYADSFVIRGD405. R12, 463PFERDISTEIYQAGS477; R16, 510VVVLSFELLHAPAT523; Un, undefined.